Tag: AIM

January 17, 2017 Off

Onzima buys remaining 51% of N4 Pharma

By Dino Mustafić

Onzima Ventures said on Tuestday it would buy another 51% of N4 Pharma Limited shares with 34609210 new ordinary shares of of 0.1p each in its capital. The acquisition should be completed by mid-April 2017.

November 17, 2015 Off

Faron Pharmaceuticals Oy joins London stock exchange

By Dino Mustafić

Faron Pharmaceuticals Oy (Faron), the clinical stage biopharmaceutical company, has started dealing its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. Tuesday after placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary.